@article{c794cba5ce1047128dce8bbcf60f18c9,
title = "Regulation of tumor angiogenesis by EZH2",
abstract = "Although VEGF-targeted therapies are showing promise, new angiogenesis targets are needed to make additional gains. Here, we show that increased Zeste homolog 2 (EZH2) expression in either tumor cells or in tumor vasculature is predictive of poor clinical outcome. The increase in endothelial EZH2 is a direct result of VEGF stimulation by a paracrine circuit that promotes angiogenesis by methylating and silencing vasohibin1 (vash1). Ezh2 silencing in the tumor-associated endothelial cells inhibited angiogenesis mediated by reactivation of VASH1, and reduced ovarian cancer growth, which is further enhanced in combination with ezh2 silencing in tumor cells. Collectively, these data support the potential for targeting ezh2 as an important therapeutic approach.",
keywords = "Cellcycle",
author = "Chunhua Lu and Han, {Hee Dong} and Mangala, {Lingegowda S.} and Rouba Ali-Fehmi and Newton, {Christopher S.} and Laurent Ozbun and Armaiz-Pena, {Guillermo N.} and Wei Hu and Stone, {Rebecca L.} and Adnan Munkarah and Ravoori, {Murali K.} and Shahzad, {Mian M.K.} and Lee, {Jeong Won} and Edna Mora and Langley, {Robert R.} and Carroll, {Amy R.} and Koji Matsuo and Spannuth, {Whitney A.} and Rosemarie Schmandt and Jennings, {Nicholas B.} and Goodman, {Blake W.} and Jaffe, {Robert B.} and Nick, {Alpa M.} and Kim, {Hye Sun} and Guven, {Eylem Ozturk} and Chen, {Ya Huey} and Li, {Long Yuan} and Hsu, {Ming Chuan} and Coleman, {Robert L.} and Calin, {George A.} and Denkbas, {Emir B.} and Lim, {Jae Yun} and Lee, {Ju Seog} and Vikas Kundra and Birrer, {Michael J.} and Hung, {Mien Chie} and Gabriel Lopez-Berestein and Sood, {Anil K.}",
note = "Funding Information: The authors thank Donna Reynolds, and Fang Wang for their technical expertise and helpful discussion. We also thank Dr. Vickie Williams for reviewing the manuscript. Portions of this work were supported by the NIH (CA 110793, 109298, P50 CA083639, P50 CA098258, CA128797, RC2GM092599), the Ovarian Cancer Research Fund, Inc. (Program Project Development Grant), the DOD (OC073399, W81XWH-10-1-0158, BC085265), NSC-96-3111-B, the Zarrow Foundation, the Marcus Foundation, the Kim Medlin Fund, and the Betty Anne Asche Murray Distinguished Professorship. W.A.S., A.M.N., A.R.C., and R.S. are supported by NCI-DHHS-NIH T32 Training Grant (T32 CA101642). K.M. is supported by the GCF/OCRF Ann Schreiber Ovarian Cancer Research grant and an award from the Meyer and Ida Gordon Foundation 2. M.M.K.S. is supported by the NIH/NICHD WRHR Grant (HD050128) and the GCF-Molly Cade Ovarian Cancer Research Grant. M.C.H. and L.Y.L. are supported by the NSC 97-3111-B-039. ",
year = "2010",
month = aug,
doi = "10.1016/j.ccr.2010.06.016",
language = "English (US)",
volume = "18",
pages = "185--197",
journal = "Cancer cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "2",
}